0
Please log in or register to do it.

John Lim, CEO of Samsung BioLogics

John Lim, CEO of Samsung BioLogics

(Seoul = Larose.VIP) Reporter Cho Hyun-young = Samsung BioLogics[207940]announced on the 15th that CEO John Lim said on the 15th, “We will secure sustainable growth momentum in the K-bio industry by spreading an organic cooperation model along with preemptive and bold investments in future technologies.”

CEO John Lim made this statement while introducing Samsung Bio’s current business status and future technology investment plans at a seminar for mutual growth of the domestic bio industry held at the Chosun Palace Seoul Gangnam Hotel on this day.

This event, held for the first time this year, was prepared by Samsung BioLogics to discuss ways to develop the bio industry with industry officials, including domestic bio ventures. Samsung Bio’s customer company GI Innovation[358570]About 60 people attended, including officials from 31 domestic bio ventures and venture capitals, including LegoChem Bioscience.

John Lim, CEO of Samsung C&T[028260]continues to invest to secure new technologies and grow in the domestic industry through a life science fund worth approximately KRW 170 billion jointly established with Samsung Bioepis and an open innovation (open cooperation) center to be built at Songdo’s second bio campus. He announced that he would continue.

In addition, at the event, presentations were made on cases of strategic partnerships between Samsung Bio and domestic bio companies and the role of funds for the growth of the domestic bio industry and bio ventures.

hyun0@yna.co.kr

Report to KakaoTalk okjebo 2024/02/16 10:49 Sent

SK Biopharmaceuticals U.S. subsidiary holds sales meeting... “Aim to be number one in epilepsy drug prescriptions”
“Migraine combined with facial flushing worsens cardiovascular health.”

Reactions

0
0
0
0
0
0
Already reacted for this post.

Reactions

Your email address will not be published. Required fields are marked *